SCHEMBL4839655

SCHEMBL4839655

CC(=O)NC1(c2ccccc2)CCN(CCC2c3ccccc3CCN2C(=O)c2ccc(C)cc2)CC1

nearest known ligand 0.46

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 5/20 0.46
OPRK1 P41145 4/20 0.46
POLB P06746 1/20 0.42
TACR3 P29371 4/20 0.42
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TACR2 P21452 2/20 0.39
TACR1 P25103 1/20 0.39
MTNR1B P49286 1/20 0.39
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4830126 0.92 TACR3 (0.45) POLBTACR3
SCHEMBL4837665 0.92 DRD3 (0.43) OPRM1OPRK1POLBTACR3ALDH1A1
SCHEMBL4836727 0.92 POLB (0.42) OPRM1OPRK1POLBTACR3ALDH1A1
SCHEMBL4840728 0.91 CYP2C19 (0.50) OPRM1OPRK1TACR3ALDH1A1CYP2C19
SCHEMBL4833088 0.87 GRIN2C (0.46) POLBTACR2TACR1
SCHEMBL4837218 0.87 GRIN2C (0.46) TACR3TACR2TACR1
SCHEMBL4830055 0.86 CYP2C19 (0.49) TACR3ALDH1A1MTNR1BCYP2C19
SCHEMBL4839170 0.84 POLB (0.41) POLBTACR3ALDH1A1KDM4EHPGD
SCHEMBL4837044 0.84 CYP2C19 (0.47) OPRM1OPRK1TACR3ALDH1A1TACR2
SCHEMBL4830077 0.84 CYP2C19 (0.47) TACR3ALDH1A1MTNR1BCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US claimed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US claimed
EP-1458714-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. Lundbeck A/S (DK) 2004-09-22 EP claimed
WO-2003051869-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. LUNDBECK A/S (DK) 2003-06-26 WO claimed
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US disclosed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US disclosed
EP-1458714-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. Lundbeck A/S (DK) 2004-09-22 EP disclosed
WO-2003051869-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. LUNDBECK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives KCNJ2, KCNK2, KCNJ11 OPRM1 1618/4885OPRK1 271/4885POLB 4382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.